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SUMMARY
A retrospective analysis ofpost-transfusion hepatitis reported to us from 1980
through 1984 revealed 16 patients. We believe that this apparently low
incidence is due to lack ofnotification and make a case for direct notification to
us of any suspected cases. Disqualification of implicated blood donors is of
prime importance in prevention of transfusion-associated hepatitis.
INTRODUCTION
Reports from different parts of the world suggest a range of incidence of post-
transfusion hepatitis from approximately 7% in the USA,' 3.4% in one Dutch
study2 to 2% in Sydney, Australia.3 The only available information for the UK
shows an incidence of 2.4% in patients undergoing cardiac surgery in Newcastle-
upon-Tyne.4 Hepatitis in these studies included clinical and sub-clinical episodes
(indicated by abnormal liver function tests after blood transfusion).
The aetiology ofjaundice in a patient who has previously received blood and/or
blood products includes hepatitis B, Epstein-Barr virus and cytomegalovirus.
Non-A, non-B hepatitis continues to be associated with blood transfusion, but
there is little published evidence of the true incidence of this condition, its clinical
importance or long-term consequences.5,6 We report on a retrospective analysis
of post-transfusion hepatitis notified to us from 1980 through 1984. Prior to this
period, notification was anecdotal and follow-up tests on blood donors were
minimal.
METHODS
All blood used in the province is collected by the Northern Ireland Blood
Transfusion Service from volunteers. Blood donors are routinely tested for
hepatitis B surface antigen (HBsAg). Since 1982, the method used is a radio-
immunoassay (RIA: Blood Products Laboratory): a sample of each unit of blood
is tested within 24 hours of the donation and prior to issue to hospital blood
banks. An aliquot of serum from each donation is stored as a reference sample at
- 20°C for 18-24 months. When an incident of post-transfusion hepatitis is
notified, all the units of blood and blood products are traced to individual donors
by the date and unique donation number. It is possible to perform additional tests
on implicated donors using the relevant stored samples ifthe notification is within
18-24 months of transfusion.
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When post-transfusion hepatitis is recognised in a patient, the first step is to
initiate laboratory tests for hepatitis A and B, cytomegalovirus and Epstein-Barr
virus. These tests are performed by the Virus Reference Laboratory, Royal
Victoria Hospital. No test is available at present for the detection of non-A, non-B
infection which remains a diagnosis of exclusion.7
The next step is notification of the patient to the NI Blood Transfusion Service
with date(s) oftransfusion and donation numbers ofall blood and blood products.
The investigations and follow-up include:
a) identification of all volunteer blood donors implicated by the unique
donation numbers;
b) the relevant stored (- 200C) donor serum is tested for hepatitis B surface
antigen (HBsAg), antibody to hepatitis B surface and core antigens (anti
HBs, anti HBc), and for liver function tests;
c) recall of donor(s) for a fresh sample of blood to repeat the tests and ensure
that implicated donors are excluded from blood donations until all investig-
ations are completed.
RESULTS
Sixteen patients with post-transfusion hepatitis were reported from 1980 to
1984 (see Table). There was a sudden increase in the number of patients
reported in 1984 which we attribute to a letter written by one of us (CB) in
December 1983, to all haematologists in the province, stressing the importance
of notification. Eleven of the 16 patients had no evidence of infection with
hepatitis B. Four patients were HBsAg positive and one patient had anti HBc of
IgM type indicating response to recent infection with hepatitis B virus. Results of
subsequent tests for HBsAg on this patient were not available to us.
The Table shows the correlation between hepatitis B infection in donors and
patients. Hepatitis B markers sought included HBsAg, anti-HBc and anti-HBs.
There was no evidence of infection in any of 22 donors for three patients positive
for HBsAg, indicating that hepatitis B infection in these three patients was not
attributable to blood transfusion (1980.1, 1984.5, 1984.7). Two donors out of
20 were implicated in the transmission of hepatitis B to two corresponding
patients. One (patient 1980.2) showed a very weak positive reaction when the
test for HBsAg was repeated but this had been missed during the initial screening
procedure. The other donor (patient 1983.2) was repeatedly HBsAg negative
and therefore would not have been identified as infective on routine screening.
Anti-HBc was the only marker in this donor and was only detected on further
investigation following the report ofpost-transfusion hepatitis. It is of interest that
one further donor out of 14 was anti-HBc positive but no evidence of hepatitis B
infection was found in the corresponding patient (1983.3).
DISCUSSION
Sensitive methods are now available for the detection of 'healthy carriers' of
hepatitis B virus. The radioimmunoassay currently used in the NI Blood
Transfusion Service for screening donors is very sensitive and calibrated to detect
very low concentrations of hepatitis B virus (HBsAg) particles. The national
minimum requirement is two British Standard Units and we are currently able to
detect the lower level of one British Standard Unit. The risk of hepatitis B
transmission through blood transfusion has, therefore, been minimised in the
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TABLE
Patients with post-transfusion hepatitis notified to the NI Blood Transfusion
Service, 1980-1984
Hepatitis B Number
Year Patients markers in ofdonors Hepatitis B markers in donors
the patient implicated
1980 1 HBsAg 7 Nil
2 anti-HBc 6 HBsAg in one donor detected
by RIA only
1981 1 Nil 2 Nil
2 Nil 15 One donor anti-HBs
1982 1 Nil 3 Nil
1983 1 Nil 2 Nil
2 HBsAg 14 Anti-HBc in one, but negative
six months later.
3 Nil 14 One donor repeatedly anti-HBc.
1984 *1 Nil 6 Nil
2 Nil 13 Nil
3 Nil 6 Nil
4 Nil 2 Nil
5 HBsAg 8 Nil
6 Nil 5 Nil
7 HBsAg 7 Nil
8 Nil 26 No follow-up: all donation
numbers not available.
HBsAg: hepatitis B surface antigen
Anti-HBc: antibody to hepatitis B core antigen
Anti-HBs: antibody to hepatitis B surface antigen
RIA: radioimmunoassay.
'Original testing by less sensitive method. **Follow.up: drug-induced.
past 5 years, but a few cases ofpost-transfusion hepatitis B will continue to occur
due to very low levels of antigen not detectable by radioimmunoassay.8 Other
transmissible agents such as the non-A, non-B agent, cytomegalovirus and
Epstein-Barr virus continue to be important in the aetiology of transfusion-
associated hepatitis. There are no simple, reliable and cost-effective screening
tests available for the detection of blood donors who are capable of transmitting
these infections.
In this report, 1 1 of 16 patients developed post-transfusion hepatitis which was
due to causes other than hepatitis B. If a diagnosis of non-A, non-B hepatitis is
suspected it is important to identify the donors implicated, in order to prevent
further transmission to other patients through future blood donations. In the
absence of a screening test,7 our present policy is empirical exclusion of any
donor implicated in two instances of post-transfusion hepatitis. It is to be noted
that, in one patient, the hepatitis was subsequently shown to be drug-induced.
Non-transfusion-related causes must be considered early in the differential
diagnosis.
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One donor who was HBsAg negative but anti-HBc positivetransmitted hepatitis B
to one patient. This is a rare occurrence but is a known possibility.8,9,10 The value
and cost-effectiveness of screening every donation for anti-HBc has been
debated."' 12,13 In Northern Ireland, the incidence of chronic asymptomatic
carriers of hepatitis B is very low: one in 1500 healthy new donors is HBsAg
positive. The risk of hepatitis B transmission from donors who are only anti-HBc
positive in our region is estimated to be negligible and does not justify the high
cost that such screening would entail.
No hepatitis B markers were detected in one patient although a donor involved
was repeatedly positive foranti-HBc. The post-transfusion hepatitis in this patient
was attributable to non-A, non-B infection. We have been unable to establish a
satisfactory duration of follow-up with regard to hepatitis B markers in this case,
although there are other reports of non-A, non-B transmission from donors who
are positive only for anti-HBc.14 Blood products including platelet concentrates,
fresh frozen plasma, cryoprecipitate and coagulation factor concentrates are
known to transmit hepatitis but none of our present series of patients were
exposed to these.
The reported incidence of post-transfusion hepatitis shows great variation, the
lowest being 2%.3 There is little doubt that the apparently negligible incidence in
Northern Ireland during the years 1980-1983 must be due to lack ofnotification.
Itis still uncertain howmanycases aremissed, and even amongasmall population
like that of Northern Ireland it is difficult to hazard a guess at the true incidence of
the disease. Of the non-B infections, non-A, non-B hepatitis is a significant
problem particularly in terms of chronic liver damage, despite the mildness ofthe
initial illness. In the absence of tests capable of detecting an infective donor, we
must rely on notification of transfusion-acquired infection and retrospective
investigation of blood donors for eventual disqualification of implicated donors.
Lack of notification may be attributed to several factors. A significant proportion
of non-A, non-B infection is sub-clinical and serum transaminase levels fluctuate
independently of clinical illness.'5 Vague symptoms after surgery or anaesthetic
may be ignored by the patient and doctor. The prolonged incubation time of
hepatitis B and moderate incubation time of non-A, non-B infection sometimes
make the correlation between transfusion and clinical illness difficult. Patients are
discharged from hospital and the present system of liaison between general
practitioners, hospital doctor and the NI Blood Transfusion Service is unsatis-
factory. There is a good case for direct notification to the NI Blood Transfusion
Service of any cases of suspected transfusion associated-infection.
We wish to thank Mrs C Shaw for typing the manuscript.
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